Retatrutide Eli Lilly: Brand Name, Manufacturer & Status

The next obesity drug everyone is talking about doesn't have a brand name yet — but the company behind it has already done this twice before, and that changes everything.

Quick Stats

Key Takeaways

• Eli Lilly is the sole manufacturer of retatrutide — the same company that made Mounjaro and Zepbound
• The drug's official research name is LY3437943 — no brand name has been announced yet
• Retatrutide is in Phase 3 trials under the TRIUMPH clinical program, with multiple studies reporting positive data in 2025–2026
• Phase 3 results show up to 26.6% average body weight loss — the highest ever recorded in a late-stage obesity trial
• Lilly's track record with tirzepatide gives real insight into how approval, pricing, and access might unfold
• FDA approval is not expected before late 2026 at the earliest, and 2027 is more realistic

Knowing who makes a drug might sound like a trivial detail. But when you're tracking something that could genuinely change how obesity is treated, the manufacturer's history shapes everything — from how fast approval moves to whether your insurance will actually cover it. Lilly isn't a newcomer here. They've already navigated this exact road with tirzepatide.

Here's everything you actually need to know about Eli Lilly's role in retatrutide's development, what the drug is called, and what happens next.

Who Makes Retatrutide? Meet Eli Lilly

Eli Lilly and Company is an Indianapolis-based pharmaceutical giant with over 145 years in the business. They're behind some of the most significant drug launches in recent memory — including Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (also tirzepatide) for obesity.

Lilly didn't stumble into GLP-1 drugs. They built their GLP-1 franchise deliberately, starting with dulaglutide (Trulicity) in 2014, then doubling down with tirzepatide's dual GIP/GLP-1 mechanism. Retatrutide is the next evolution — a triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously.

That triple mechanism is what makes it different from anything on the market today. Semaglutide (Wegovy/Ozempic) hits one receptor. Tirzepatide hits two. Retatrutide hits three, and the early data suggests that extra lever produces meaningfully greater weight loss. If you want a deeper look at the science, check out our guide on what is retatrutide.

What Is Retatrutide's Official Brand Name?

Short answer: there isn't one yet.

The drug is currently identified by its research compound designation: LY3437943. That "LY" prefix is Lilly's internal coding system — every molecule they develop gets one. You'll see LY3437943 referenced in clinical trial registries, published papers in the New England Journal of Medicine, and Lilly's own press releases.

Brand names only get assigned when a company prepares to submit for FDA approval — typically in the months leading up to or during the NDA (New Drug Application) filing. Lilly hasn't filed yet, so they haven't announced a name.

This is worth knowing because a lot of websites throw around "retatrutide" as if it's the brand name. It's not — it's the International Nonproprietary Name (INN), the generic scientific identifier. The branded name will be something entirely different, likely a trademarked word that Lilly's marketing team spent months developing (think: how "Ozempic" and "Mounjaro" sound nothing like "semaglutide" and "tirzepatide").

For now, if you're searching for this drug, use: retatrutide, LY3437943, or Eli Lilly retatrutide.

Lilly's Track Record: Why It Actually Matters

You might wonder why the manufacturer is relevant if the drug is still years from your pharmacy shelf. Here's why it matters more than most people think.

Lilly has already done the GLP-1 approval process twice — Mounjaro was approved for type 2 diabetes in 2022, Zepbound for obesity in November 2023. They know the FDA's expectations, they have established manufacturing infrastructure, and they have real-world data on what it takes to bring a GLP-1 class drug to market at scale.

That matters for a few specific reasons:

Speed. Lilly already has relationships with FDA reviewers who know their safety and efficacy data submission format. That doesn't mean shortcuts, but it does mean fewer back-and-forth delays.

Manufacturing. One of the biggest bottlenecks after Mounjaro approval was supply. Lilly got caught somewhat flat-footed and had to scramble to ramp manufacturing capacity. They've since invested billions in new facilities specifically to avoid that happening again with the next generation of drugs.

Insurance access. The pattern with tirzepatide was frustrating — initially limited coverage, slow formulary decisions, expensive without insurance. Lilly launched patient savings programs and fought insurance denials with clinical data. Expect a similar playbook with retatrutide, but with more leverage now that Lilly's obesity drugs are established in the market.

The TRIUMPH Clinical Program Explained

Lilly named their Phase 3 retatrutide program TRIUMPH — standing for TRiple-hormone receptor agonist for the treatment of obesIty and related coMorbidities PH**. It's a suite of large clinical trials studying retatrutide across different patient populations.

The trials that have reported data or are underway include:

• TRIUMPH-4 (completed, Dec 2025): Tested the two highest doses in adults with obesity and knee osteoarthritis. Results: average weight loss up to 26.6% at the higher dose — the most weight loss ever documented in a Phase 3 obesity trial. Notably, knee pain also improved significantly.
• TRANSCEND-T2D-1 (Phase 3, Mar 2026): Evaluated retatrutide in adults with type 2 diabetes. Lilly reported positive topline results showing statistically significant reductions in both A1c (blood sugar) and body weight.
• TRIUMPH-1 and TRIUMPH-2: Testing retatrutide in broader obesity populations, with results expected mid-2026.
• TRIUMPH-8: Currently recruiting adults with obesity or overweight (NCT07232719).

The breadth of these trials is deliberate. Lilly wants approval across multiple indications — not just obesity, but diabetes, cardiovascular disease, and osteoarthritis. That expands the potential patient base significantly and strengthens the case for insurance coverage.

What the Phase 3 Data Actually Shows

The numbers coming out of the TRIUMPH trials are genuinely remarkable, even by the high standards that Mounjaro already set.

TRIUMPH-4 results, announced December 2025: up to 71.2 lbs average weight loss at the highest dose in adults with obesity. That's not a typo. On a placebo-adjusted basis, body weight decreased by 26.6%. For context, semaglutide (Wegovy) produces around 15% weight loss, and tirzepatide (Zepbound) achieves up to 22.5%.

Phase 2 data published in the New England Journal of Medicine (2023) showed 24.2% weight loss at 48 weeks — already the highest ever reported for a single-agent obesity medication at the time.

The TRANSCEND-T2D-1 results from March 2026 showed retatrutide significantly lowered HbA1c (the 3-month blood sugar average) in people with type 2 diabetes, alongside meaningful weight reduction.

One caution worth flagging: TRIUMPH-4 data also identified a new safety signal called dysesthesia — an abnormal sense of touch — in some participants. It's not been seen at this magnitude in earlier trials. Lilly is monitoring it closely, and it may factor into the FDA review timeline.

How Does Retatrutide Compare to Mounjaro and Zepbound?

All three of these drugs came out of Lilly's labs, but they're meaningfully different molecules. Think of them as an evolution rather than competitors.

Mounjaro / Zepbound (tirzepatide): Dual agonist targeting GIP and GLP-1. Approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Produces up to ~22.5% weight loss.

Retatrutide (LY3437943): Triple agonist targeting GIP, GLP-1, and glucagon. Still investigational. Phase 3 data shows up to 26.6% weight loss — a noticeable step up.

The glucagon receptor adds something important: it directly increases energy expenditure and fat burning. The GLP-1 and GIP components suppress appetite and slow gastric emptying. Together, they hit weight from multiple biological angles at once.

Curious how retatrutide stacks up against semaglutide specifically? We've broken it down in detail: retatrutide vs semaglutide.

Current FDA Status: Where Things Stand in 2026

As of Q1 2026, retatrutide remains investigational — meaning it is not FDA approved and not legally available as a prescription medication in the United States.

Lilly has not yet submitted an NDA (New Drug Application) for retatrutide, though the TRIUMPH trial data coming in through 2025–2026 sets up that filing. Based on current timelines:

• NDA submission: Expected late 2026 (after TRIUMPH-1 and TRIUMPH-2 data are available)
• FDA review period: 6–12 months following acceptance
• Potential approval: Late 2027 at the most realistic estimate, possibly late 2026 under a priority review scenario

This is later than some media coverage suggests. Several articles written in 2024 projected 2026 approval based on accelerated assumptions. With the dysesthesia signal now in the data and multiple TRIUMPH trials still reporting, the runway is longer than the optimistic case.

For a more detailed approval timeline breakdown, see our article on when will retatrutide be available.

What Approval Could Mean for Access and Cost

If you've watched the tirzepatide rollout, you already have a preview of what retatrutide's launch might look like — and it's a mixed picture.

Pricing: Lilly priced Zepbound at around $1,059/month list price without insurance. Based on inflation and retatrutide's positioning as a premium next-gen product, expect similar or slightly higher launch pricing. The out-of-pocket cost without insurance will be significant.

Insurance coverage: GLP-1 drugs for obesity have had a rough go with insurers. Medicare still doesn't cover obesity-only GLP-1 prescriptions (it requires a covered comorbidity). Commercial insurance is spotty. Lilly's Mounjaro/Zepbound experience gives them data to push back on denials, and they've been vocal advocates for coverage reform.

Savings programs: Lilly has run savings card programs for Zepbound that bring costs under $200/month for eligible commercially-insured patients. They'll almost certainly do something similar with retatrutide.

Step therapy: Insurers will likely require patients to try cheaper options first — meaning semaglutide or tirzepatide — before approving retatrutide. This is frustrating but expected.

The bottom line: even with approval, access won't be immediate or equal. The same dynamics that made Zepbound hard to get for many patients will apply here, at least initially.

Where Retatrutide Fits in Lilly's Pipeline

Retatrutide isn't a standalone bet — it's a key piece of Lilly's long-term strategy to dominate the cardiometabolic drug market.

Lilly is also developing orforglipron, an oral GLP-1 pill, and exploring next-generation combinations beyond the triple agonist. They're simultaneously expanding indications for tirzepatide (heart failure, sleep apnea, NASH). The obesity drug market is expected to reach $100 billion annually by 2030, and Lilly intends to own a major share of it.

Retatrutide's role in that picture: the premium injectable option for patients who need maximum efficacy — those with severe obesity, multiple comorbidities, or who haven't responded adequately to tirzepatide. It's not necessarily meant to replace Zepbound; it's meant to sit above it in the portfolio.

Frequently Asked Questions

Who manufactures retatrutide?

Eli Lilly and Company, headquartered in Indianapolis, Indiana, is the sole manufacturer and developer of retatrutide. The drug was developed entirely in-house as part of Lilly's GLP-1 research program, which also produced Mounjaro and Zepbound.

What is retatrutide's brand name?

Retatrutide does not have an official brand name yet. Its research designation is LY3437943. A trademarked brand name will be announced when Lilly submits its NDA to the FDA, which has not happened as of early 2026.

Is retatrutide FDA approved?

No. Retatrutide is still an investigational drug as of 2026. Multiple Phase 3 TRIUMPH trials are underway or reporting data, but Lilly has not yet submitted an NDA. FDA approval is not expected before late 2026, with 2027 being the more realistic estimate.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors. Retatrutide hits all three — GLP-1, GIP, and glucagon receptors. That triple action appears to produce greater weight loss than either predecessor based on current clinical data.

What is the TRIUMPH program?

TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide, covering obesity, type 2 diabetes, cardiovascular disease, and osteoarthritis populations. As of early 2026, multiple TRIUMPH trials have reported positive topline results, with additional data expected through 2026.

How much weight loss does retatrutide cause?

Phase 3 TRIUMPH-4 results (Dec 2025) showed an average weight loss of up to 26.6% body weight on a placebo-adjusted basis, or up to 71.2 lbs on average at the highest dose. Phase 2 results showed 24.2% at 48 weeks. Both represent the highest efficacy numbers ever reported for an obesity drug in their respective trial phases.

Will retatrutide be covered by insurance?

There's no way to know for certain until it's approved and Lilly negotiates formulary placement. Based on the tirzepatide experience, initial coverage will be inconsistent — especially for obesity without a listed comorbidity. Commercial insurers will likely require prior authorization and possibly step therapy. Medicare coverage for obesity-only indications remains a legislative question.

Where Things Stand Right Now

Retatrutide is unambiguously Eli Lilly's drug, built on the same research foundation that produced two already-successful obesity medications. The brand name doesn't exist yet, but the compound does — and so does a growing mountain of Phase 3 evidence supporting it.

The track record here is real. Lilly has shown they can take a complex hormonal molecule from Phase 2 excitement to real-world prescription drug, twice. The TRIUMPH program is delivering. The question is no longer whether retatrutide works — the data is compelling — but how long the regulatory path takes and whether the approval lands with a safety profile insurers and patients can work with.

If you're thinking about future access, the best move is staying informed as TRIUMPH data rolls in and watching for Lilly's NDA announcement. That's when the timeline gets real.

Want to explore more about this drug? Check out these related guides:

• What is retatrutide?
• When will retatrutide be available?
• Retatrutide vs semaglutide: how do they compare?

Currently researching peptides? Ascension Peptides offers rigorously tested research compounds with transparent lab verification.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide (LY3437943) is an investigational drug that has not received FDA approval. Do not attempt to obtain or use retatrutide outside of an approved clinical trial. Always consult a licensed healthcare provider before making any decisions about medications or weight management treatments. Eli Lilly has not reviewed or endorsed this content.